-
Autor
Abdelrahman Soliman, Dina Sameh 1 Al-Shemari, Salem 1 Alcoceba, Miguel 1 Angelopoulou, Maria 1 Antic, Darko 1 Aurran-Schleinitz, Thérèse 1 Bacchiarri, Francesca 1 Bellido, Mar 1 Biderman, Bella 1 Bijou, Fontanet 1 Bosch, Francesc 1 Calleja, Anne 1 Cassin, Ramona 1 Catherwood, Mark 1 Chamou, Dimitra 1 Chatzidimitriou, Anastasia 1 Chatzikonstantinou, Thomas 1 Chatzileontiadou, Sofia 1 Christian, Amy 1 Claus, Rainer 1
-
Pracoviště
1st Faculty of Medicine 1st Departmen... 1 4th Department of Internal Medicine H... 1 Antalya Training and Research Hospita... 1 Biological Haematology Department Dij... 1 Central European Institute of Technol... 1 Clinic for Hematology University Clin... 1 Clinic for Hematology and Stem Cell T... 1 Clinical Haematology Belfast City Hos... 1 Consultative Hematology Department wi... 1 Department and Clinic of Hematology B... 1 Department of Clinical Hematology ICO... 1 Department of Haematology Athens Medi... 1 Department of Haematology Royal Bourn... 1 Department of Haematology University ... 1 Department of Haematology University ... 1 Department of Haematooncology Univers... 1 Department of Hemato Oncology Institu... 1 Department of Hematological Malignanc... 1 Department of Hematology Centre Hospi... 1 Department of Hematology Hospital Uni... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Abdelrahman Soliman, Dina Sameh 1 Al-Shemari, Salem 1 Alcoceba, Miguel 1 Angelopoulou, Maria 1 Antic, Darko 1 Aurran-Schleinitz, Thérèse 1 Bacchiarri, Francesca 1 Bellido, Mar 1 Biderman, Bella 1 Bijou, Fontanet 1 Bosch, Francesc 1 Calleja, Anne 1 Cassin, Ramona 1 Catherwood, Mark 1 Chamou, Dimitra 1 Chatzidimitriou, Anastasia 1 Chatzikonstantinou, Thomas 1 Chatzileontiadou, Sofia 1 Christian, Amy 1 Claus, Rainer 1
-
Pracoviště
1st Faculty of Medicine 1st Departmen... 1 4th Department of Internal Medicine H... 1 Antalya Training and Research Hospita... 1 Biological Haematology Department Dij... 1 Central European Institute of Technol... 1 Clinic for Hematology University Clin... 1 Clinic for Hematology and Stem Cell T... 1 Clinical Haematology Belfast City Hos... 1 Consultative Hematology Department wi... 1 Department and Clinic of Hematology B... 1 Department of Clinical Hematology ICO... 1 Department of Haematology Athens Medi... 1 Department of Haematology Royal Bourn... 1 Department of Haematology University ... 1 Department of Haematology University ... 1 Department of Haematooncology Univers... 1 Department of Hemato Oncology Institu... 1 Department of Hematological Malignanc... 1 Department of Hematology Centre Hospi... 1 Department of Hematology Hospital Uni... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
PubMed Central od 2018
Europe PubMed Central od 2018
Elsevier Open Access Journals od 2018
ROAD: Directory of Open Access Scholarly Resources od 2018
PubMed
38033506
DOI
10.1016/j.eclinm.2023.102307
Knihovny.cz E-zdroje
BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. METHODS: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. FINDINGS: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). INTERPRETATION: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS. FUNDING: AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026.
- Publikační typ
- časopisecké články MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.